It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The rising incidence of bone pathologies such as osteoporosis and osteoarthritis is negatively affecting the functional status of millions of patients worldwide. The genetic component of these multifactorial pathologies is far from being fully understood, but in recent years several epigenetic mechanisms involved in the pathophysiology of these bone diseases have been identified. The aim of the present study was to compare the serum expression of four miRNAs in women with hip fragility fracture (OF group), osteoarthritis requiring hip replacement (OA group) and control women (Ctrl group). Serum expression of miR-497-5p, miR-155-5p, miR-423-5p and miR-365-3p was determined in a sample of 23 OA women, 25 OF women and 52 Ctrl women. Data shown that women with bone pathologies have higher expression of miR-497 and miR-423 and lower expression of miR-155 and miR-365 than control subjects. Most importantly, miR-497 was identified as an excellent discriminator between OA group and control group (AUC: 0.89, p < 0.000) and acceptable in distinguishing from the OF group (AUC: 0.76, p = 0.002). Our data suggest that circulating miR-497 may represent a significant biomarker of OA, a promising finding that could contribute towards future early-stage diagnosis of this disease. Further studies are required to establish the role of miR-155, miR-423 and miR-365 in bone pathologies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 INCLIVA Health Research Institute, Research Unit, Valencia, Spain (GRID:grid.429003.c)
2 University of Valencia, Department of Cellular Biology, Functional Biology and Physical Anthropology, Burjassot, Spain (GRID:grid.5338.d) (ISNI:0000 0001 2173 938X)
3 University of Valencia, Department of Pediatrics, Obstetrics and Gynecology, Valencia, Spain (GRID:grid.5338.d) (ISNI:0000 0001 2173 938X)
4 INCLIVA Health Research Institute, Research Unit, Valencia, Spain (GRID:grid.429003.c); University of Valencia, Department of Genetics, Burjassot, Spain (GRID:grid.5338.d) (ISNI:0000 0001 2173 938X)
5 INCLIVA Institute of Health Research, Orthopedic Surgery and Traumatology, Clinic Hospital, Valencia, Spain (GRID:grid.5338.d)